Watch Demo

Influenza Vaccine Market Research Report by Vaccine Type, Age Group, Administration Route, Distribution Channel, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

Influenza Vaccine Market Research Report by Vaccine Type, Age Group, Administration Route, Distribution Channel, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
  • Publish Date:July 2022

  • Number of Pages:238

  • Report ID:6398521

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

Influenza Vaccine Market Research Report by Vaccine Type (Inactivated, Live Attenuated, and Recombinant), Age Group, Administration Route, Distribution Channel, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

The Global Influenza Vaccine Market size was estimated at USD 7,285.36 million in 2022 and expected to reach USD 7,921.37 million in 2023, projecting growth at a CAGR of 8.97% to reach USD 14,491.61 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Influenza Vaccine Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Influenza Vaccine Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Influenza Vaccine Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Influenza Vaccine Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the Global Influenza Vaccine Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Vaccine Type, the market is studied across Inactivated, Live Attenuated, and Recombinant.

Based on Age Group, the market is studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination.

Based on Administration Route, the market is studied across Intramuscular, Intranasal, and Oral.

Based on Distribution Channel, the market is studied across Government Medical Office, Hospital & Clinic, Retail Pharmacy, and Urgent Care Unit.

Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Influenza Vaccine Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Influenza Vaccine Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Influenza Vaccine Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Influenza Vaccine Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Influenza Vaccine Market, including Abbott Laboratories, AstraZeneca PLC, Bayer AG, BioDiem, BiondVax Pharmaceuticals Ltd., Bristol-Myers Squibb Company, CanSino Biologics Inc., Daiichi Sankyo Company, Limited, Emergent BioSolutions Inc., Eurocept Group, Fluart Innovative Vaccines Kft., Gamma Vaccines Pty Ltd, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer Inc., Sanofi S.A., Seqirus GmbH, Serum Institute of India Pvt. Ltd., Sinovac Biotech Ltd., and Swedish Orphan Biovitrum AB.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Influenza Vaccine Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Influenza Vaccine Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Influenza Vaccine Market?
4. What is the competitive strategic window for opportunities in the Global Influenza Vaccine Market?
5. What are the technology trends and regulatory frameworks in the Global Influenza Vaccine Market?
6. What is the market share of the leading vendors in the Global Influenza Vaccine Market?
7. What modes and strategic moves are considered suitable for entering the Global Influenza Vaccine Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Prevalence of Respiratory Disorders
5.1.1.2. Immunization as a Major Public Health Measures for the Prevention of Influenza Virus Infection
5.1.1.3. Clinical Trials and Vaccine Developments in Pipeline for Seasonal Influenzas
5.1.1.4. Government Initiatives Supporting Respiratory Health
5.1.2. Restraints
5.1.2.1. Lack of Inadequate Delivery Infrastructure & Limited Awareness
5.1.3. Opportunities
5.1.3.1. Increasing R&D Expenditure by Leading Market Players
5.1.3.2. Increasing Vaccine Availability through Distribution and Development Collaborations
5.1.3.3. Several Vaccine Candidates under Development against Animal Influenza A Virus
5.1.4. Challenges
5.1.4.1. Customers Trust and Confidence in Respiratory Disease Vaccination
5.1.4.2. Vaccine Research and Development are getting Challenged by the Constant Variations in Strains
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization
5.8.1. COVID: Eye on Proactive Vaccine Development
5.8.2. Shift to Retail Pharmacies for Immunizations

6. Influenza Vaccine Market, by Vaccine Type
6.1. Introduction
6.2. Inactivated
6.3. Live Attenuated
6.4. Recombinant

7. Influenza Vaccine Market, by Age Group
7.1. Introduction
7.2. Adolescent Vaccination
7.3. Adult Vaccination
7.4. Infant Vaccination

8. Influenza Vaccine Market, by Administration Route
8.1. Introduction
8.2. Intramuscular
8.3. Intranasal
8.4. Oral

9. Influenza Vaccine Market, by Distribution Channel
9.1. Introduction
9.2. Government Medical Office
9.3. Hospital & Clinic
9.4. Retail Pharmacy
9.5. Urgent Care Unit

10. Americas Influenza Vaccine Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Influenza Vaccine Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Influenza Vaccine Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Product Portfolio Analysis, By Key Player
13.5. Competitive Scenario
13.5.1. Merger & Acquisition
13.5.2. Agreement, Collaboration, & Partnership
13.5.3. New Product Launch & Enhancement
13.5.4. Investment & Funding
13.5.5. Award, Recognition, & Expansion

14. Company Usability Profiles
14.1. Abbott Laboratories
14.2. AstraZeneca PLC
14.3. Bayer AG
14.4. BioDiem
14.5. BiondVax Pharmaceuticals Ltd.
14.6. Bristol-Myers Squibb Company
14.7. CanSino Biologics Inc.
14.8. Daiichi Sankyo Company, Limited
14.9. Emergent BioSolutions Inc.
14.10. Eurocept Group
14.11. Fluart Innovative Vaccines Kft.
14.12. Gamma Vaccines Pty Ltd
14.13. GlaxoSmithKline PLC
14.14. Johnson & Johnson
14.15. Merck & Co., Inc.
14.16. Pfizer Inc.
14.17. Sanofi S.A.
14.18. Seqirus GmbH
14.19. Serum Institute of India Pvt. Ltd.
14.20. Sinovac Biotech Ltd.
14.21. Swedish Orphan Biovitrum AB

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing

List of Figures

FIGURE 1. GLOBAL INFLUENZA VACCINE MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL INFLUENZA VACCINE MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL INFLUENZA VACCINE MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL INFLUENZA VACCINE MARKET DYNAMICS
FIGURE 11. GLOBAL INFLUENZA VACCINE MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2022 VS 2030 (%)
FIGURE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL INFLUENZA VACCINE MARKET COMPETITIVE STRATEGIC WINDOW, BY VACCINE TYPE, 2030
FIGURE 15. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
FIGURE 18. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2022 VS 2030 (%)
FIGURE 19. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 20. GLOBAL INFLUENZA VACCINE MARKET COMPETITIVE STRATEGIC WINDOW, BY AGE GROUP, 2030
FIGURE 21. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, 2018-2030 (USD MILLION)
FIGURE 22. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT VACCINATION, 2018-2030 (USD MILLION)
FIGURE 23. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INFANT VACCINATION, 2018-2030 (USD MILLION)
FIGURE 24. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2022 VS 2030 (%)
FIGURE 25. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 26. GLOBAL INFLUENZA VACCINE MARKET COMPETITIVE STRATEGIC WINDOW, BY ADMINISTRATION ROUTE, 2030
FIGURE 27. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
FIGURE 28. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
FIGURE 29. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
FIGURE 30. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
FIGURE 31. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 32. GLOBAL INFLUENZA VACCINE MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION CHANNEL, 2030
FIGURE 33. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GOVERNMENT MEDICAL OFFICE, 2018-2030 (USD MILLION)
FIGURE 34. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL & CLINIC, 2018-2030 (USD MILLION)
FIGURE 35. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
FIGURE 36. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY URGENT CARE UNIT, 2018-2030 (USD MILLION)
FIGURE 37. AMERICAS INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 38. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 39. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 40. AMERICAS INFLUENZA VACCINE MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 41. ARGENTINA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 42. BRAZIL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 43. CANADA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 44. MEXICO INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 45. UNITED STATES INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 46. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 47. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 48. UNITED STATES INFLUENZA VACCINE MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 49. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 51. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 52. ASIA-PACIFIC INFLUENZA VACCINE MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 53. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. CHINA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. INDIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. INDONESIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. JAPAN INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. MALAYSIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. SINGAPORE INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 61. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 62. TAIWAN INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 63. THAILAND INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 64. VIETNAM INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 66. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 67. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 68. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 69. DENMARK INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. EGYPT INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. FINLAND INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. FRANCE INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. GERMANY INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. ISRAEL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. ITALY INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. NIGERIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. NORWAY INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. POLAND INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 80. QATAR INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 81. RUSSIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 82. SAUDI ARABIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 83. SOUTH AFRICA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 84. SPAIN INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 85. SWEDEN INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 86. SWITZERLAND INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 87. TURKEY INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 88. UNITED ARAB EMIRATES INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 89. UNITED KINGDOM INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 90. GLOBAL INFLUENZA VACCINE MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 91. GLOBAL INFLUENZA VACCINE MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 92. GLOBAL INFLUENZA VACCINE MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. GLOBAL INFLUENZA VACCINE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT VACCINATION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INFANT VACCINATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRAMUSCULAR, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GOVERNMENT MEDICAL OFFICE, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GOVERNMENT MEDICAL OFFICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY GOVERNMENT MEDICAL OFFICE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL & CLINIC, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL & CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY HOSPITAL & CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY URGENT CARE UNIT, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY URGENT CARE UNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL INFLUENZA VACCINE MARKET SIZE, BY URGENT CARE UNIT, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 57. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 58. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 59. ARGENTINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. CANADA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 66. CANADA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 68. CANADA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 69. CANADA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. MEXICO INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 71. MEXICO INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 72. MEXICO INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 73. MEXICO INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 74. MEXICO INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 87. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 88. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. CHINA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 93. CHINA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 94. CHINA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 95. CHINA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 96. CHINA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. INDIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 98. INDIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 99. INDIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 100. INDIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 101. INDIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 102. INDONESIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 103. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 104. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 105. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 106. INDONESIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. JAPAN INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 108. JAPAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 109. JAPAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 110. JAPAN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 111. JAPAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 113. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 114. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 115. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 116. MALAYSIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 119. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 120. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 121. PHILIPPINES INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 125. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 126. SINGAPORE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH KOREA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. THAILAND INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 138. THAILAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 139. THAILAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. THAILAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 141. THAILAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. DENMARK INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 154. DENMARK INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 155. DENMARK INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. DENMARK INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 157. DENMARK INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 158. EGYPT INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 159. EGYPT INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 160. EGYPT INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. EGYPT INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 162. EGYPT INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. FINLAND INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 164. FINLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 165. FINLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 166. FINLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 167. FINLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. FRANCE INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 169. FRANCE INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 170. FRANCE INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 171. FRANCE INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 172. FRANCE INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. GERMANY INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 174. GERMANY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 175. GERMANY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 176. GERMANY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 177. GERMANY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 178. ISRAEL INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 179. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 180. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 183. ITALY INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 184. ITALY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 185. ITALY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 186. ITALY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 187. ITALY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 189. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 190. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 191. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 192. NETHERLANDS INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 193. NIGERIA INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 194. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 195. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 197. NIGERIA INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 198. NORWAY INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 199. NORWAY INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 200. NORWAY INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 201. NORWAY INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 202. NORWAY INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. POLAND INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 204. POLAND INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 205. POLAND INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 206. POLAND INFLUENZA VACCINE MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2030 (USD MILLION)
TABLE 207. POLAND INFLUENZA VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. QATAR INFLUENZA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 209. QATAR INFLUENZA VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 210. QATAR INFLUENZA VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)

Please contact our Customer Support Center to get the complete Table of Contents

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.